Market Trends Dyne reports new long-term data from Phase 1/2 DELIVER trial of DYNE-251 (DYN:NASDAQ)By admin8996erT0allMarch 17, 2025 Dyne Therapeutics (NASDAQ:DYN) on Monday reported new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating…
Market Trends Dyne stock gains on FDA fast track tag (DYN:NASDAQ)By admin8996erT0allJanuary 21, 2025 hapabapa Dyne Therapeutics (NASDAQ:DYN) announced Tuesday that the U.S. Food and Drug Administration (FDA) issued fast-track designation for DYNE-101, an…
